Predictive factors for sustained virological response after treatment with pegylated interferon α-2a and ribavirin in patients infected with HCV genotypes 2 and 3

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Niederau, Claus ^a   Mauss, Stefan ^b   Schober, Andreas ^c   Stoehr, Albrecht ^d   Zimmermann, Tim ^e   Waizmann, Michael ^f   Moog, Gero ^g   Pape, Stefan ^h   Weber, Bernd ⁱ   Isernhagen, Konrad ^j   Sandow, Petra ^k   Bokemeyer, Bernd ^l   Alshuth, Ulrich ^m   Steffens, Hermann ⁿ   Hüppe, Dietrich ^o  

^a St Josef Hospital Oberhausen   (Germany)

^b Center for HIV and Hepatogastroenterology   (Germany)

^c Center for Gastroenterology   (Germany)

^d Ifi Institute for Interdisciplinary Medicine   (Germany)

^e JOHANNES GUTENBERG UNIVERSITY   (Germany)

^f Medcenter Leipzig   (Germany)

^g Center for Gastroenterology   (Germany)

^h Center for Gastroenterology   (Germany)

ⁱ Praxiszentrum Friedrichsplatz   (Germany)

^j Clinic for General Medicine   (Germany)

^k General Practice   (Germany)

^l KLINIKUM MINDEN   (Germany)

^m ROCHE INNOVATION CENTER MUNICH   (Germany)

ⁿ Practice for Internal Medicine/Cardiology   (Germany)

^o Center of Gastroenterology   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; APRI SCORE; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE DURATION; DRUG USE; FEMALE; FOLLOW UP; GERMANY; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OBSERVATIONAL STUDY; PHYSICIAN; PREDICTION; PROSPECTIVE STUDY; SCORING SYSTEM; SEX DIFFERENCE; TREATMENT RESPONSE; CLINICAL TRIAL; GENETICS; GENOTYPE; HEPACIVIRUS; IMMUNOLOGY; MIDDLE AGED;

HEPATITIS C VIRUS;

ADULT; COHORT STUDIES; FEMALE; GENOTYPE; GERMANY; HEPACIVIRUS; HEPATITIS C; HUMANS; MALE; MIDDLE AGED;

EID: 84907202528     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107592     Document Type: Article

References (51)

1. Sarrazin C, Berg T, Ross RS, Schirmacher P, Wedemeyer H, et al. (2010) Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection. Z Gastroenterol: 48: 289-351.
2. European Association for the Study of the Liver (2011) EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol: 55: 245-64.
3. Ghany MG, Strader DB, Thomas DL, Seeff LB (2009) Diagnosis, management, and treatment of hepatitis C: an update. Hepatology: 49: 1335-1374.
4. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, PEGASYS International Study Group, et al. (2004) Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med: 140: 346-355.
5. Dalgard O, Bjøro K, Hellum KB, Myrvang B, Ritland S, et al. (2004) Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology: 40: 1260-1265.
6. Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, et al. (2005) Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med: 352: 2609-2617.
7. von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, et al. (2005) Peginterferonalpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology: 129: 522-527.
8. Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, et al. (2007) ACCELERATE Investigators. ACCELERATE Investigators. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med: 357: 124-133.
9. Dalgard O, Bjøro K, Ring-Larsen H, Bjornsson E, Holberg-Petersen M, et al. (2008) North-C Group. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology: 47: 35-42.
10. Lagging M, Langeland N, Pedersen C, Färkkilä M, Buhl MR, et al. (2008) NORDynamIC Study Group. NORDynamIC Study Group. Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology: 47: 1837-1845.
11. Mangia A, Minerva N, Bacca D, Cozzolongo R, Agostinacchio E, et al. (2009) Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection. Hepatology: 49: 358-363.
12. Mecenate F, Pellicelli AM, Barbaro G, Romano M, Barlattani A, et al. (2010) Club Epatologi Ospedalieri (CLEO) Group. Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the cleo trial. BMC Gastroenterol: 19: 10-21.
13. Slavenburg S, Weggelaar I, van Oijen MG, Drenth JP (2009) Optimal length of antiviral therapy in patients with hepatitis C virus genotypes 2 and 3: a meta-analysis. Antivir Ther: 14: 1139-1148.
14. Petta S, Craxi A (2011) Optimal therapy in hepatitis C virus genotypes 2 and 3 patients. Liver Int: 31: 36-44.
15. Sarin SK, Kumar CK (2012) Treatment of patients with genotype 3 chronic hepatitis C-current and future therapies. Liver Int: 32: 141-145.
16. Probst A, Dang T, Bochud M, Egger M, Negro F, et al. (2011) Role of hepatitis C virus genotype 3 in liver fibrosis progression-a systematic review and meta-analysis. J Viral Hepat: 18: 745-759.
17. Hüppe D, Zehnter E, Mauss S, Böker K, Lutz T, et al. (2008) Epidemiology of chronic hepatitis C in Germany-an analysis of 10, 326 patients in hepatitis centres and outpatient units. Z Gastroenterol: 46: 34-44.
18. Niederau C, Hüppe D, Zehnter E, Möller B, Heyne R, et al. (2012) Chronic hepatitis C: treat or wait? Medical decision making in clinical practice. W J Gastroenterology: 18: 1339-1347.
19. Niederau C, Mauss S, Böker K, Lutz T, Heyne R, et al. (2013) Non-compliance with guidelines for treatment of hepatitis C is frequent in daily practice. Eur J Gastroenterol Hepatol 2013, 2013 Jun 11. [Epub ahead of print]
20. Strader DB, Wright T, Thomas DL, Seeff LB (2004) American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology: 39: 1147-1171.
21. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, et al. (2003) A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology: 38: 518-526.
22. Lörke J, Erhardt A, Vogt C, Häussinger D (2007) Nicht invasive Diagnostik der Leberzirrhose. Dtsch Arztebl: 104: 1752-1757.
23. Kruger FC, Daniels CR, Kidd M, Swart G, Brundyn K, et al. (2011) APRI: A simple bedside marker for advanced fibrosis that can avoid liver biopsy in patients with NAFLD/NASH. S Afr Med J: 101: 477-480.
24. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, et al. (2006) Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology: 43: 1317-1325.
25. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, et al. (2013) Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med: 368: 1878-1887.
26. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, et al. (2013) POSITRON Study; FUSION Study. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med: 368: 1867-1877.
27. Petta S, Craxì A (2012) Therapeutic algorithms for chronic hepatitis C in the DAA era during the current economic crisis: whom to treat? How to treat? When to treat? BMC Infect Dis: 12 S2-S3.
28. Brown R, Jacobson I, Afdhal N, Freilich B, Pauley MP, et al. (2006) Risk factors for relapse in genotype 3 high viral load patients with hepatitis C in the WIN-R trial. Hepatology: 44: 609-610.
29. Bochud PY, Cai T, Overbeck K, Bochud M, Dufour JF, et al. (2009) Swiss Hepatitis C Cohort Study Group. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol: 51: 655-666.
30. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, et al. (2011) A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol: 9: 509-516.
31. Felmlee DJ, Hafirassou ML, Lefevre M, Baumert TF, Schuster C (2013) Hepatitis C Virus, Cholesterol and lipoproteins-Impact for the viral life cycle and pathogenesis of liver disease. Viruses: 5: 1292-132
32. Cacoub P, Ouzan D, Melin P, Lang JP, Rotily M, et al. (2008) Patient education improves adherence to peg-interferon and ribavirin in chronic genotype 2 or 3 hepatitis C virus infection: a prospective, real-life, observational study. World J Gastroenterol: 14: 6195-6203.
33. Andriulli A, Mangia A, Iacobellis A, Ippolito A, Leandro G, et al. (2008) Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. Aliment Pharmacol Ther: 28: 397-404.
34. Inoue Y, Hiramatsu N, Oze T, Yakushijin T, Mochizuki K, et al. (2010) Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses. J Viral Hepat: 17: 336-344.
35. Pedersen C, Alsiö A, Lagging M, Langeland N, Färkkilä M, et al. (2011) NOR DynamicIC Study Group. Ribavirin plasma concentration is a predictor of sustained virological response in patients treated for chronic hepatitis C virus genotype 2/3 infection. J Viral Hepat: 18: 245-251.
36. Mauss S, Berger F, Goelz J, Jacob B, Schmutz G (2004) A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology: 40: 120-4.
37. Lindenburg CE, Lambers FA, Urbanus AT, Schinkel J, Jansen PL, et al. (2011) Hepatitis C testing and treatment among active drug users in Amsterdam: results from the DUTCH-C project. Eur J Gastroenterol Hepatol: 23: 23-31.
38. Neukam K, Mira JA, Gilabert I, Claro E, Vázquez MJ, et al. (2012) Efficacy of chronic hepatitis C therapy with pegylated interferon and ribavirin in patients on methadone maintenance treatment. Eur J Clin Microbiol Infect Dis: 31: 1225-32.
39. Bonkovsky HL, Tice AD, Yapp RG, Bodenheimer HC Jr, Monto A, et al. (2008) Efficacy and safety of peginterferon alfa-2a/ribavirin in methadone maintenance patients: randomized comparison of direct observed therapy and self-administration. Am J Gastroenterol: 103: 2757-65.
40. Martinez AD, Dimova R, Marks KM, Beeder AB, Zeremski M, et al. (2012) Integrated internist-addiction medicine-hepatology model for hepatitis C management for individuals on methadone maintenance J Viral Hep: 19: 47-54.
41. Barth H, Liang TJ, Baumert TF (2006) Hepatitis C virus entry: molecular biology and clinical implications. Hepatology: 44: 527-535.
42. Syed GH, Amako Y, Siddiqui A (2010) Hepatitis C virus hijacks host lipid metabolism. Trends Endocrinol Metab: 21: 33-40.
43. Sanyal AJ (2011) Role of insulin resistance and hepatic steatosis in the progression of fibrosis and response to treatment in hepatitis C. Liver Int: 31: 23-28.
44. Rubbia-Brandt L, Fabris P, Paganin S, Leandro G, Male PJ, et al. (2004) Steatosis affects chronic hepatitis C progression in a genotype specific way. Gut: 53: 406-412.
45. Hezode C, Roudot-Thoraval F, Zafrani ES, Dhumeaux D, Pawlotsky JM (2004) Different mechanisms of steatosis in hepatitis C virus genotypes 1 and 3 infections. J Viral Hepat: 11: 455-458.
46. Patton HM, Patel K, Behling C, Bylund D, Blatt LM, et al. (2004) The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol: 40: 484-490.
47. Clark PJ, Thompson AJ, Vock DM, Kratz LE, Tolun AA, et al. (2012) Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype-specific manner. Hepatology: 56: 49-56.
48. Serfaty L, Andreani T, Giral P, Carbonell N, Chazouilleres O, et al. (2001) Hepatitis C virus induced hypobeta-lipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol: 34: 428-434.
49. Corey KE, Kane E, Munroe C, Barlow LL, Zheng H, et al. (2009) Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up. Hepatology: 50: 1030-1037.
50. Ramcharran D, Wahed AS, Conjeevaram HS, Evans RW, Wang T, et al. (2010) Virahep-C Study Group. Associations between serum lipids and hepatitis C antiviral treatment efficacy. Hepatology: 52: 854-863.
51. Harrison SA, Rossaro L, Hu KQ, Patel K, Tillmann H, et al. (2010) Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. Hepatology: 52: 864-874.